"Chemotherapy and immunotherapy remain the primary treatments for metastatic melanoma. Currently, DTIC (Dicarbazine) is the only FDA-approved chemotherapeutic treatment. Response rates are often under 20 percent, with less than 5 percent of patients achieving a complete response. In addition, DTIC must undergo hepatic activation by the active metabolite monomethyl triazenoimidazole carboxamide (MTIC), and cannot cross the blood-brain barrier, so it is ineffective for patients with hepatic dysfunction or CNS metastases."Not a good choice for brain tumors.
I guess I did not make the grade.
On to the next trial Please!
No comments:
Post a Comment